We further propose that the local application of the anti‐CD47/anti‐CD24 antibodies, combined with CAR‐T, tumor vaccines, immune checkpoint inhibitors, or other systemic immunotherapies will likely improve the overall efficacy for clinical treatment of glioblastoma (Figure 3). This evidence concerns the gene CD47 and glioblastoma.